Tooth Bud
Kyoto University Hospital and Toregem Biopharma completed Phase I of TRG-035 — an anti-USAG-1 monoclonal antibody that reactivates dormant third-set tooth buds in adults by blocking the protein that keeps them suppressed. Phase II funding was secured in mid-2026. Click Inject TRG-035 to watch USAG-1 suppressors get neutralized and dormant buds grow into new teeth. August 2026.
Drug
TRG-035
Target
USAG-1 protein
Phase I
Safe · Oct 2024
Phase II
Funded · 2026
TRG-035 → third-set tooth regeneration pathway